|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000102024 |
Summary for PLS3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000102024 | Gene symbol | PLS3 |
| Gene name | plastin 3 | |
| HGNC | 9091 | |
| Entrez ID | 5358 | |
| Gene type | protein_coding | |
| Synonyms | PLS3|T-plastin | |
| UniProtAcc | P13797 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for PLS3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PLS3 | 2.23e+03 | -1.50e+00 | 2.01e-01 | -7.45e+00 | 9.44e-14 | 9.35e-13 | KIRP |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PLS3 | 4.49e+03 | -1.06e+00 | 1.62e-01 | -6.57e+00 | 5.18e-11 | 3.60e-10 | KIRC |
Top |
Sex-biased somatic mutation for PLS3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for PLS3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.55e-01 | 1.31e-01 | 2.86e+00 | 4.30e-03 | 1.91e-02 | 1.25e-01 |
| KIRC | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.62e-01 | 4.87e-02 | 1.37e+01 | 1.54e-42 | 3.26e-41 | 1.14e-01 |
| KIRC | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.55e-01 | 4.20e-02 | 1.39e+01 | 3.93e-44 | 8.95e-43 | 1.13e-01 |
| LUAD | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 3.72e-01 | 5.32e-01 | -6.46e+00 | 1.03e-10 | 1.34e-09 | -1.60e-01 |
| LUAD | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.00e-01 | 5.38e-02 | 1.75e+01 | 1.89e-68 | 7.33e-67 | 1.46e-01 |
| LUAD | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.91e-01 | 5.04e-02 | 1.80e+01 | 1.31e-72 | 5.79e-71 | 1.40e-01 |
| LGG | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 7.53e-01 | 8.72e-01 | -1.17e+01 | 1.61e-31 | 1.31e-30 | -1.19e-01 |
| LGG | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.79e-01 | 9.15e-01 | -1.13e+01 | 7.75e-30 | 6.16e-29 | -1.36e-01 |
| LGG | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 4.94e-01 | 3.35e-01 | 9.24e+00 | 2.50e-20 | 1.73e-19 | 1.59e-01 |
| LGG | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.43e-01 | 4.11e-02 | 1.73e+01 | 2.19e-67 | 3.24e-66 | 1.02e-01 |
| LGG | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.45e-01 | 4.45e-02 | 1.71e+01 | 7.25e-66 | 1.04e-64 | 1.01e-01 |
| HNSC | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.08e-01 | 8.07e-02 | 1.50e+01 | 7.31e-51 | 2.09e-49 | 1.27e-01 |
| HNSC | cg27162304 | chrX:115561591 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.45e-01 | 4.04e-02 | 1.52e+01 | 2.89e-52 | 8.52e-51 | 1.04e-01 |
| HNSC | cg16524492 | chrX:115561981 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.48e-01 | 4.76e-02 | 1.46e+01 | 4.12e-48 | 1.11e-46 | 1.00e-01 |
| LUSC | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 6.15e-01 | 8.05e-01 | -5.29e+00 | 1.23e-07 | 9.19e-07 | -1.90e-01 |
| LUSC | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.75e-01 | 5.30e-02 | 1.26e+01 | 2.82e-36 | 4.13e-35 | 1.22e-01 |
| LUSC | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.75e-01 | 5.25e-02 | 1.27e+01 | 1.07e-36 | 1.58e-35 | 1.22e-01 |
| SKCM | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 6.45e-01 | 8.41e-01 | -9.48e+00 | 2.47e-21 | 1.96e-20 | -1.96e-01 |
| SKCM | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 6.88e-01 | 8.35e-01 | -9.51e+00 | 1.94e-21 | 1.55e-20 | -1.47e-01 |
| SKCM | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 6.52e-01 | 7.62e-01 | -6.86e+00 | 6.79e-12 | 4.25e-11 | -1.10e-01 |
| SKCM | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.44e-01 | 4.28e-02 | 1.62e+01 | 3.39e-59 | 5.95e-58 | 1.01e-01 |
| BLCA | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.02e-01 | 7.64e-02 | 1.38e+01 | 1.67e-43 | 3.27e-42 | 1.26e-01 |
| BLCA | cg27162304 | chrX:115561591 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.42e-01 | 4.11e-02 | 1.29e+01 | 4.81e-38 | 8.24e-37 | 1.00e-01 |
| STAD | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 4.03e-01 | 6.12e-01 | -4.56e+00 | 5.15e-06 | 2.90e-05 | -2.09e-01 |
| STAD | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.11e-01 | 7.94e-02 | 1.37e+01 | 7.88e-43 | 1.69e-41 | 1.32e-01 |
| STAD | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.60e-01 | 5.53e-02 | 1.33e+01 | 2.00e-40 | 4.02e-39 | 2.05e-01 |
| STAD | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.49e-01 | 5.42e-02 | 1.30e+01 | 8.20e-39 | 1.58e-37 | 1.95e-01 |
| KIRP | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.50e-01 | 4.22e-02 | 1.18e+01 | 4.70e-32 | 1.45e-30 | 1.08e-01 |
| KIRP | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.97e-01 | 4.44e-02 | 1.16e+01 | 6.82e-31 | 1.92e-29 | 1.53e-01 |
| SARC | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 7.28e-01 | 8.55e-01 | -4.15e+00 | 3.30e-05 | 1.90e-04 | -1.27e-01 |
| SARC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.43e-01 | 8.65e-01 | -6.60e+00 | 4.13e-11 | 3.87e-10 | -1.22e-01 |
| SARC | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 7.18e-01 | 8.34e-01 | -5.90e+00 | 3.62e-09 | 3.06e-08 | -1.15e-01 |
| PCPG | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 6.16e-01 | 8.60e-01 | -9.39e+00 | 5.87e-21 | 5.99e-20 | -2.43e-01 |
| PCPG | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 6.41e-01 | 8.00e-01 | -6.50e+00 | 7.81e-11 | 4.46e-10 | -1.58e-01 |
| PCPG | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 6.25e-01 | 8.13e-01 | -6.84e+00 | 8.00e-12 | 4.76e-11 | -1.88e-01 |
| PAAD | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 5.69e-01 | 7.19e-01 | -8.43e+00 | 3.44e-17 | 4.28e-16 | -1.50e-01 |
| PAAD | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 3.14e-01 | 2.01e-01 | 6.67e+00 | 2.51e-11 | 2.20e-10 | 1.13e-01 |
| PAAD | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 1.75e-01 | 7.33e-02 | 1.08e+01 | 2.53e-27 | 5.53e-26 | 1.02e-01 |
| PAAD | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.19e-01 | 4.56e-02 | 1.11e+01 | 1.62e-28 | 3.97e-27 | 1.74e-01 |
| PAAD | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.02e-01 | 4.99e-02 | 1.09e+01 | 9.98e-28 | 2.25e-26 | 1.52e-01 |
| READ | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.72e-01 | 7.30e-02 | 7.54e+00 | 4.87e-14 | 5.15e-13 | 1.99e-01 |
| READ | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 3.56e-01 | 3.92e-02 | 8.24e+00 | 1.69e-16 | 2.33e-15 | 3.17e-01 |
| READ | cg27162304 | chrX:115561591 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.99e-01 | 3.40e-02 | 7.96e+00 | 1.77e-15 | 2.11e-14 | 1.65e-01 |
| READ | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 3.58e-01 | 4.05e-02 | 8.11e+00 | 5.20e-16 | 6.64e-15 | 3.18e-01 |
| READ | cg16524492 | chrX:115561981 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.05e-01 | 3.82e-02 | 7.92e+00 | 2.36e-15 | 2.78e-14 | 1.66e-01 |
| GBM | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 7.29e-01 | 8.87e-01 | -4.40e+00 | 1.07e-05 | 6.23e-05 | -1.59e-01 |
| GBM | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.84e-01 | 9.16e-01 | -4.56e+00 | 5.22e-06 | 3.22e-05 | -1.32e-01 |
| GBM | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 4.39e-01 | 1.79e-01 | 4.46e+00 | 8.26e-06 | 4.93e-05 | 2.60e-01 |
| GBM | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.18e-01 | 4.00e-02 | 5.65e+00 | 1.58e-08 | 1.33e-07 | 1.78e-01 |
| GBM | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.97e-01 | 4.13e-02 | 5.49e+00 | 4.11e-08 | 3.28e-07 | 1.55e-01 |
| ESCA | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.04e-01 | 8.31e-02 | 6.68e+00 | 2.35e-11 | 2.29e-10 | 1.21e-01 |
| ESCA | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.63e-01 | 5.40e-02 | 7.16e+00 | 8.23e-13 | 9.50e-12 | 2.09e-01 |
| ESCA | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.47e-01 | 5.51e-02 | 6.78e+00 | 1.22e-11 | 1.22e-10 | 1.92e-01 |
| LAML | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 7.32e-01 | 8.91e-01 | -5.41e+00 | 6.17e-08 | 2.46e-07 | -1.59e-01 |
| LAML | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.67e-01 | 8.69e-01 | -3.94e+00 | 8.15e-05 | 2.73e-04 | -1.02e-01 |
| LAML | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.31e-01 | 9.64e-02 | 7.85e+00 | 4.06e-15 | 2.40e-14 | 1.34e-01 |
| LAML | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.53e-01 | 1.13e-01 | 7.02e+00 | 2.19e-12 | 1.11e-11 | 1.39e-01 |
| LAML | cg16524492 | chrX:115561981 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.06e-01 | 1.03e-01 | 5.59e+00 | 2.26e-08 | 9.21e-08 | 1.03e-01 |
| THYM | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.67e-01 | 4.33e-02 | 8.85e+00 | 8.63e-19 | 7.90e-18 | 1.24e-01 |
| MESO | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 4.11e-01 | 6.48e-01 | -3.37e+00 | 7.40e-04 | 3.88e-03 | -2.38e-01 |
| MESO | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 4.50e-01 | 7.34e-01 | -4.03e+00 | 5.48e-05 | 3.50e-04 | -2.84e-01 |
| UVM | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 7.56e-01 | 8.64e-01 | -2.80e+00 | 5.14e-03 | 1.29e-02 | -1.08e-01 |
| ACC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.49e-01 | 9.11e-01 | -4.58e+00 | 4.69e-06 | 3.69e-05 | -1.63e-01 |
| ACC | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 1.45e-01 | 3.87e-02 | 5.36e+00 | 8.25e-08 | 7.60e-07 | 1.06e-01 |
| ACC | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 7.15e-01 | 8.43e-01 | -3.42e+00 | 6.18e-04 | 3.50e-03 | -1.28e-01 |
| ACC | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 7.37e-01 | 8.61e-01 | -4.52e+00 | 6.24e-06 | 4.85e-05 | -1.25e-01 |
| ACC | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 3.03e-01 | 1.78e-01 | 3.05e+00 | 2.27e-03 | 1.00e-02 | 1.25e-01 |
| DLBC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 6.37e-01 | 7.81e-01 | -3.46e+00 | 5.49e-04 | 2.12e-03 | -1.43e-01 |
| CHOL | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 3.91e-01 | 1.76e-01 | 3.53e+00 | 4.10e-04 | 1.80e-03 | 2.14e-01 |
| CHOL | cg16221059 | chrX:115561158 | CGI:chrX:115561087-115562322 | promoter | 2.50e-01 | 7.73e-02 | 4.23e+00 | 2.29e-05 | 1.38e-04 | 1.73e-01 |
| CHOL | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 3.57e-01 | 5.12e-02 | 4.58e+00 | 4.55e-06 | 3.43e-05 | 3.06e-01 |
| CHOL | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.80e-01 | 5.33e-02 | 4.14e+00 | 3.49e-05 | 2.01e-04 | 2.26e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 4.68e-01 | 3.47e-01 | 3.70e+00 | 2.18e-04 | 4.06e-04 | 1.21e-01 |
| KIRC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 4.19e-01 | 2.84e-01 | 3.72e+00 | 2.03e-04 | 3.80e-04 | 1.35e-01 |
| LUAD | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 5.32e-01 | 7.53e-01 | 3.07e+00 | 2.17e-03 | 3.72e-03 | -2.21e-01 |
| LUAD | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 5.45e-01 | 7.28e-01 | -2.18e+00 | 2.91e-02 | 3.22e-02 | -1.83e-01 |
| LUSC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.33e-01 | 6.30e-01 | 2.37e+00 | 1.76e-02 | 2.16e-02 | 1.02e-01 |
| LIHC | cg12289482 | chrX:115560023 | CGI:chrX:115561087-115562322 | promoter | 2.65e-01 | 5.10e-01 | 2.89e+00 | 3.88e-03 | 5.26e-03 | -2.45e-01 |
| LIHC | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 3.81e-01 | 5.57e-01 | 1.98e+00 | 4.71e-02 | 4.75e-02 | -1.77e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 5.35e-01 | 6.39e-01 | -5.19e+00 | 2.11e-07 | 4.19e-07 | -1.04e-01 |
| BRCA | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 3.74e-01 | 2.69e-01 | 6.55e+00 | 5.74e-11 | 1.54e-10 | 1.06e-01 |
| BRCA | cg08990057 | chrX:115561277 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.54e-01 | 1.15e-01 | 7.63e+00 | 2.34e-14 | 8.13e-14 | 1.39e-01 |
| BRCA | cg21539234 | chrX:115561702 | CGI:chrX:115561087-115562322 | promoter,gene body | 2.55e-01 | 1.11e-01 | 6.82e+00 | 9.18e-12 | 2.62e-11 | 1.45e-01 |
| KIRC | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 6.24e-01 | 5.10e-01 | 2.43e+00 | 1.53e-02 | 2.26e-02 | 1.15e-01 |
| LUAD | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 4.37e-01 | 5.65e-01 | -2.50e+00 | 1.23e-02 | 1.82e-02 | -1.28e-01 |
| THCA | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 7.09e-01 | 8.11e-01 | -2.91e+00 | 3.63e-03 | 6.34e-03 | -1.02e-01 |
| BLCA | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 4.55e-01 | 6.90e-01 | -2.83e+00 | 4.66e-03 | 1.09e-02 | -2.35e-01 |
| BLCA | cg11824101 | chrX:115560321 | CGI:chrX:115561087-115562322 | promoter | 4.47e-01 | 6.65e-01 | -2.05e+00 | 4.02e-02 | 4.30e-02 | -2.18e-01 |
| BLCA | cg18134562 | chrX:115560768 | CGI:chrX:115561087-115562322 | promoter | 2.67e-01 | 3.68e-01 | -2.60e+00 | 9.25e-03 | 1.66e-02 | -1.00e-01 |
| LIHC | cg05052271 | chrX:115560203 | CGI:chrX:115561087-115562322 | promoter | 2.64e-01 | 4.43e-01 | -2.48e+00 | 1.32e-02 | 1.73e-02 | -1.79e-01 |
Top |
Exon skipping events with PSI in TCGA for PLS3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for PLS3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for PLS3 |
| TFs related to PLS3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | CDC5L | PLS3 | 3.72e+00 | 6.02e-03 | 4.76e+00 | 9.90e-01 | Female-biased |
| DLBC | FOXP1 | PLS3 | 3.34e+00 | 9.39e-03 | 4.24e+00 | 9.80e-01 | Female-biased |
| DLBC | HOXB7 | PLS3 | 3.03e+00 | 5.07e-03 | 4.10e+00 | 9.82e-01 | Female-biased |
| DLBC | MEIS1 | PLS3 | 3.41e+00 | 5.99e-03 | 4.44e+00 | 9.87e-01 | Female-biased |
| DLBC | NKX2-2 | PLS3 | 3.00e+00 | 3.41e-03 | 4.19e+00 | 9.86e-01 | Female-biased |
| DLBC | NKX6-3 | PLS3 | 3.27e+00 | 5.34e-03 | 4.33e+00 | 9.86e-01 | Female-biased |
| DLBC | ONECUT1 | PLS3 | 4.08e+00 | 1.12e-02 | 4.95e+00 | 9.86e-01 | Female-biased |
| DLBC | PBX2 | PLS3 | 3.17e+00 | 5.85e-03 | 4.21e+00 | 9.83e-01 | Female-biased |
| DLBC | SOX6 | PLS3 | 3.13e+00 | 6.80e-03 | 4.12e+00 | 9.81e-01 | Female-biased |
| DLBC | ZNF354A | PLS3 | 2.78e+00 | 2.54e-03 | 4.04e+00 | 9.84e-01 | Female-biased |
| LAML | ZNF334 | PLS3 | 3.64e+00 | 1.03e-02 | 4.53e+00 | 9.81e-01 | Female-biased |
| LAML | ZNF418 | PLS3 | 3.10e+00 | 2.07e-03 | 4.40e+00 | 9.88e-01 | Female-biased |
| PLS3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for PLS3 |
| RBPs related to ES in PLS3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | FMR1 | exon_skip_512039 | 8.29e+00 | 1.05e-02 | 8.59e+00 | 9.83e-01 | Female-biased |
| UVM | KHDRBS3 | exon_skip_512026 | 9.25e+00 | 1.69e-02 | 9.52e+00 | 9.80e-01 | Female-biased |
| THYM | FMR1 | exon_skip_512039 | 8.36e+00 | 9.64e-03 | 8.68e+00 | 9.85e-01 | Female-biased |
| LIHC | ZCRB1 | exon_skip_512033 | 1.26e+01 | 2.00e-03 | 1.32e+01 | 9.98e-01 | Female-biased |
| COAD | ZCRB1 | exon_skip_512033 | 1.25e+01 | 8.55e-03 | 1.28e+01 | 9.91e-01 | Female-biased |
| THCA | ZCRB1 | exon_skip_512033 | 1.29e+01 | 1.00e+00 | 1.22e+01 | 9.98e-05 | Male-biased |
| MESO | ZCRB1 | exon_skip_512033 | 1.31e+01 | 9.91e-01 | 1.28e+01 | 8.98e-03 | Male-biased |
| KICH | ZCRB1 | exon_skip_512033 | 1.24e+01 | 1.21e-03 | 1.29e+01 | 9.98e-01 | Female-biased |
| BLCA | FMR1 | exon_skip_512039 | 8.84e+00 | 9.93e-01 | 8.28e+00 | 1.93e-03 | Male-biased |
| SARC | ZCRB1 | exon_skip_512033 | 1.26e+01 | 1.33e-03 | 1.32e+01 | 9.98e-01 | Female-biased |
| PLS3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000102024 |
| CpG Site: cg10800483 | |
| Position to Gene: gene,enhancer | |
| Male Effect: -0.302034481862607 | |
| Female Effect: - | |
 | Gene ID: ENSG00000102024 |
| CpG Site: cg11824101 | |
| Position to Gene: promoter | |
| Male Effect: -0.161387238347221 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10800483 | chrX:115564011 | gene,enhancer | -0.302034481862607 | 3.25537360107898e-07 | -0.37654852112324544 | 5.036322447681341e-09 | LUSC |
| cg11824101 | chrX:115560321 | promoter | -0.161387238347221 | 4.20500487879445e-06 | -0.34874639234368277 | 4.5675944760442596e-08 | LUSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of PLS3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000102024 | PLS3 | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C0029408 | Degenerative polyarthritis | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C0086743 | Osteoarthrosis Deformans | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C3806712 | BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 18 | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| ENSG00000102024 | PLS3 | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
